Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Nephrotoxicity of Common Drugs Used in Clinical Practice

Nephrotoxicity of Common Drugs Used in Clinical Practice Abstract • Drug-induced nephrotoxicity is an increasingly recognized complication of a wide variety of therapeutic agents. The nephrotoxicity of three of the most commonly used drug groups are reviewed in this article. They include antibiotics, radiocontrast agents, and nonsteroidal anti-inflammatory drugs. Since the clinical spectrum of drug-induced nephrotoxicity is broad, it is imperative that the clinician recognize these nephrotoxic syndromes while they are reversible with discontinuation of the offending drug. (Arch Intern Med 1987;147:1213-1218) References 1. Hou SH, Bushinsky DA, Wish JB, et al: Hospital-acquired renal insufficiency: A prospective study. Am J Med 1983;74:243-248.Crossref 2. Humes HD, Weinberg JM: Toxic nephropathies , in Brenner BM, Rector FC (eds): The Kidney . Philadelphia, WB Saunders Co, 1986. 3. Smith CR, Lipsky JJ, Laskin OL, et al: Double-blind comparison of the nephrotoxicity and auditory toxicity of gentamicin and tobramycin. N Engl J Med 1980;302:1106-1109.Crossref 4. Smith CR, Baughman KL, Edwards CQ, et al: Controlled comparison of amikacin and gentamicin. N Engl J Med 1977;296:349-354.Crossref 5. Bennett WM: Aminoglycoside nephrotoxicity. Nephron 1983;35:73-77.Crossref 6. Sastrasinh M, Knaus TC, Winberg JM, et al: Identification of the aminoglycoside binding site of renal brush border membranes. J Pharmacol Exp Ther 1982;222:350-358. 7. Mela-Riker LM, Widener LL, Houghton DC, et al: Renal mitochondrial integrity during continuous gentamicin treatment. Biochem Pharmacol 1986;35:979-984.Crossref 8. DeBroe M, Guiliano RA, Verpooten GA: Choice of drug and dosage regimen: Two important risk factors for aminoglycoside nephrotoxicity. Am J Med 1986;80:115-118.Crossref 9. Sawyers CL, Moore RD, Lerner SA, et al: A model for predicting nephrotoxicity in patients treated with aminoglycosides. J Infect Dis 1986;153:1062-1068.Crossref 10. Wade JC, Smith CR, Petty BG, et al: Cephalothin plus an aminoglycoside is more nephrotoxic than methicillin plus an aminoglycoside. Lancet 1978;2:604-606.Crossref 11. Atkinson RM, Currie JP, Davis B, et al: Acute toxicity of cephaloridine, an antibiotic derived from cephalosporin C. Toxicol Appl Pharmacol 1966;8:398-406.Crossref 12. Corwin HL, Korbet SM, Schwartz MM: Clinical correlates of eosinophiluria. Arch Intern Med 1985;145:1097-1099.Crossref 13. Nolan CR, Anger MS, Kelleher SP: Eosinophiluria: A new method of detection and definition of the clinical spectrum. N Engl J Med 1986;315: 1516-1519.Crossref 14. Linton AL, Clark WF, Driedger AA, et al: Acute interstitial nephritis due to drugs. Ann Intern Med 1980;93:735-741.Crossref 15. Galpin JE, Shinaberger JH, Stanley TM, et al: Acute interstitial nephritis due to methicillin. Am J Med 1978;65:756-765.Crossref 16. Berkseth RO, Kjellstrand CM: Radiologic contrast-induced nephropathy. Med Clin North Am 1984;68:351-370. 17. Talner LB, Davidson AJ: Renal hemodynamic effects of contrast media. Invest Radiol 1968;3:310-317.Crossref 18. Fang LS, Sirota RA, Ebert TH, et al: Low fractional excretion of sodium with contrast media—induced acute renal failure. Arch Intern Med 1980;140:531-533.Crossref 19. Humes HD, Hunt DA, White MD: Direct toxic effect of the radiocontrast agent diatrizoate on renal proximal tubular cells. Am J Physiol 1987;21:F246-F255. 20. Postlewaite AE, Kelley WN: Uricosuric effect of radiocontrast agents. Ann Intern Med 1971;74:845-852.Crossref 21. Gelman LM, Rowe JW, Coggins CH: Effects of an angiographic contrast agent on renal function. Cardiovasc Med 1979;4:313-320. 22. Harkonen S, Kjellstrand C: Contrast nephropathy. Am J Nephrol 1981;1:69.Crossref 23. Van Zee BE, Hoy WE, Talley TE, et al: Renal injury associated with intravenous pyelography in nondiabetic and diabetic patients. Ann Intern Med 1978;89:51-54.Crossref 24. D'Elia J, Gleason RE, Alday M, et al: Nephrotoxicity from angiographic contrast material: A prospective study. Am J Med 1982;72: 719-725.Crossref 25. Taliercio CP, Vlietstra RE, Fisher LD, et al: Risks for renal dysfunction with cardiac angiography. AJR 1986;104:501-504. 26. Anto HR, Chou SY, Porush JC, et al: Infusion intravenous pyelography and renal function: Effects of hypertonic mannitol in patients with chronic renal failure. Arch Intern Med 1981;141:1652-1656.Crossref 27. Old CW, Duarte CM, Lehrner LM, et al: A prospective evaluation of mannitol in the prevention of radiocontrast acute renal failure, abstracted. Clin Res 1981;29:472A. 28. L'Eorme M: Nonsteroidal anti-inflammatory drugs and the kidney. Br Med J 1986;2:1621-1622.Crossref 29. Blackshear JL, Davidman M, Stillman MT: Identification of risk for renal insufficiency from nonsteroidal anti-inflammatory drugs. Arch Intern Med 1983;143:1130-1134.Crossref 30. Clive DM, Stoff JS: Renal syndromes associated with nonsteroidal antiinflammatory drugs. N Engl J Med 1984;310:563-572.Crossref 31. Aiken JW, Vane JR: Intrarenal prostaglandin release attenuated the renal vasoconstrictor activity of angiotensin. J Pharmacol Exp Ther 1973;184:678-687. 32. Ciabattoni G, Cinotti GA, Pierucci A, et al: Effects on sulindac and ibuprofen in patients with chronic glomerular disease: Evidence for the dependence of renal function on prostacyclin. N Engl J Med 1984;310: 279-283.Crossref 33. Brezin JH, Katz SM, Schwartz AB, et al: Reversible renal failure and nephrotic syndrome associated with nonsteroidal anti-inflammatory drugs. N Engl J Med 1979;301:1271-1273.Crossref 34. Norby LH, Weidig J, Ranwell P, et al: Possible role for impaired renal prostaglandin production in the pathogenesis of hyporeninaemic hypoaldosteronism. Lancet 1979;2:1118. 35. Tan SY, Shapiro R, Franco R, et al: Indomethacin-induced prostaglandin inhibition with hyperkalemia: A reversible cause of hyporeninemic hypoaldosteronism. Ann Intern Med 1979;90:783-785.Crossref 36. Lum GM, Aisenbrey GA, Dunn MJ, et al: In vivo effect of indomethacin to potentiate the renal medullary cyclic AMP response to vasopressin. J Clin Invest 1977;59:8-13.Crossref 37. Hart D, Ward M, Lifschitz M: Suprofen-related nephrotoxicity: A distinct clinical syndrome. Ann Intern Med 1987;106:235-238.Crossref http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Archives of Internal Medicine American Medical Association

Nephrotoxicity of Common Drugs Used in Clinical Practice

Loading next page...
 
/lp/american-medical-association/nephrotoxicity-of-common-drugs-used-in-clinical-practice-ejZnHMfGQH

References (37)

Publisher
American Medical Association
Copyright
Copyright © 1987 American Medical Association. All Rights Reserved.
ISSN
0003-9926
eISSN
1538-3679
DOI
10.1001/archinte.1987.00370070027003
Publisher site
See Article on Publisher Site

Abstract

Abstract • Drug-induced nephrotoxicity is an increasingly recognized complication of a wide variety of therapeutic agents. The nephrotoxicity of three of the most commonly used drug groups are reviewed in this article. They include antibiotics, radiocontrast agents, and nonsteroidal anti-inflammatory drugs. Since the clinical spectrum of drug-induced nephrotoxicity is broad, it is imperative that the clinician recognize these nephrotoxic syndromes while they are reversible with discontinuation of the offending drug. (Arch Intern Med 1987;147:1213-1218) References 1. Hou SH, Bushinsky DA, Wish JB, et al: Hospital-acquired renal insufficiency: A prospective study. Am J Med 1983;74:243-248.Crossref 2. Humes HD, Weinberg JM: Toxic nephropathies , in Brenner BM, Rector FC (eds): The Kidney . Philadelphia, WB Saunders Co, 1986. 3. Smith CR, Lipsky JJ, Laskin OL, et al: Double-blind comparison of the nephrotoxicity and auditory toxicity of gentamicin and tobramycin. N Engl J Med 1980;302:1106-1109.Crossref 4. Smith CR, Baughman KL, Edwards CQ, et al: Controlled comparison of amikacin and gentamicin. N Engl J Med 1977;296:349-354.Crossref 5. Bennett WM: Aminoglycoside nephrotoxicity. Nephron 1983;35:73-77.Crossref 6. Sastrasinh M, Knaus TC, Winberg JM, et al: Identification of the aminoglycoside binding site of renal brush border membranes. J Pharmacol Exp Ther 1982;222:350-358. 7. Mela-Riker LM, Widener LL, Houghton DC, et al: Renal mitochondrial integrity during continuous gentamicin treatment. Biochem Pharmacol 1986;35:979-984.Crossref 8. DeBroe M, Guiliano RA, Verpooten GA: Choice of drug and dosage regimen: Two important risk factors for aminoglycoside nephrotoxicity. Am J Med 1986;80:115-118.Crossref 9. Sawyers CL, Moore RD, Lerner SA, et al: A model for predicting nephrotoxicity in patients treated with aminoglycosides. J Infect Dis 1986;153:1062-1068.Crossref 10. Wade JC, Smith CR, Petty BG, et al: Cephalothin plus an aminoglycoside is more nephrotoxic than methicillin plus an aminoglycoside. Lancet 1978;2:604-606.Crossref 11. Atkinson RM, Currie JP, Davis B, et al: Acute toxicity of cephaloridine, an antibiotic derived from cephalosporin C. Toxicol Appl Pharmacol 1966;8:398-406.Crossref 12. Corwin HL, Korbet SM, Schwartz MM: Clinical correlates of eosinophiluria. Arch Intern Med 1985;145:1097-1099.Crossref 13. Nolan CR, Anger MS, Kelleher SP: Eosinophiluria: A new method of detection and definition of the clinical spectrum. N Engl J Med 1986;315: 1516-1519.Crossref 14. Linton AL, Clark WF, Driedger AA, et al: Acute interstitial nephritis due to drugs. Ann Intern Med 1980;93:735-741.Crossref 15. Galpin JE, Shinaberger JH, Stanley TM, et al: Acute interstitial nephritis due to methicillin. Am J Med 1978;65:756-765.Crossref 16. Berkseth RO, Kjellstrand CM: Radiologic contrast-induced nephropathy. Med Clin North Am 1984;68:351-370. 17. Talner LB, Davidson AJ: Renal hemodynamic effects of contrast media. Invest Radiol 1968;3:310-317.Crossref 18. Fang LS, Sirota RA, Ebert TH, et al: Low fractional excretion of sodium with contrast media—induced acute renal failure. Arch Intern Med 1980;140:531-533.Crossref 19. Humes HD, Hunt DA, White MD: Direct toxic effect of the radiocontrast agent diatrizoate on renal proximal tubular cells. Am J Physiol 1987;21:F246-F255. 20. Postlewaite AE, Kelley WN: Uricosuric effect of radiocontrast agents. Ann Intern Med 1971;74:845-852.Crossref 21. Gelman LM, Rowe JW, Coggins CH: Effects of an angiographic contrast agent on renal function. Cardiovasc Med 1979;4:313-320. 22. Harkonen S, Kjellstrand C: Contrast nephropathy. Am J Nephrol 1981;1:69.Crossref 23. Van Zee BE, Hoy WE, Talley TE, et al: Renal injury associated with intravenous pyelography in nondiabetic and diabetic patients. Ann Intern Med 1978;89:51-54.Crossref 24. D'Elia J, Gleason RE, Alday M, et al: Nephrotoxicity from angiographic contrast material: A prospective study. Am J Med 1982;72: 719-725.Crossref 25. Taliercio CP, Vlietstra RE, Fisher LD, et al: Risks for renal dysfunction with cardiac angiography. AJR 1986;104:501-504. 26. Anto HR, Chou SY, Porush JC, et al: Infusion intravenous pyelography and renal function: Effects of hypertonic mannitol in patients with chronic renal failure. Arch Intern Med 1981;141:1652-1656.Crossref 27. Old CW, Duarte CM, Lehrner LM, et al: A prospective evaluation of mannitol in the prevention of radiocontrast acute renal failure, abstracted. Clin Res 1981;29:472A. 28. L'Eorme M: Nonsteroidal anti-inflammatory drugs and the kidney. Br Med J 1986;2:1621-1622.Crossref 29. Blackshear JL, Davidman M, Stillman MT: Identification of risk for renal insufficiency from nonsteroidal anti-inflammatory drugs. Arch Intern Med 1983;143:1130-1134.Crossref 30. Clive DM, Stoff JS: Renal syndromes associated with nonsteroidal antiinflammatory drugs. N Engl J Med 1984;310:563-572.Crossref 31. Aiken JW, Vane JR: Intrarenal prostaglandin release attenuated the renal vasoconstrictor activity of angiotensin. J Pharmacol Exp Ther 1973;184:678-687. 32. Ciabattoni G, Cinotti GA, Pierucci A, et al: Effects on sulindac and ibuprofen in patients with chronic glomerular disease: Evidence for the dependence of renal function on prostacyclin. N Engl J Med 1984;310: 279-283.Crossref 33. Brezin JH, Katz SM, Schwartz AB, et al: Reversible renal failure and nephrotic syndrome associated with nonsteroidal anti-inflammatory drugs. N Engl J Med 1979;301:1271-1273.Crossref 34. Norby LH, Weidig J, Ranwell P, et al: Possible role for impaired renal prostaglandin production in the pathogenesis of hyporeninaemic hypoaldosteronism. Lancet 1979;2:1118. 35. Tan SY, Shapiro R, Franco R, et al: Indomethacin-induced prostaglandin inhibition with hyperkalemia: A reversible cause of hyporeninemic hypoaldosteronism. Ann Intern Med 1979;90:783-785.Crossref 36. Lum GM, Aisenbrey GA, Dunn MJ, et al: In vivo effect of indomethacin to potentiate the renal medullary cyclic AMP response to vasopressin. J Clin Invest 1977;59:8-13.Crossref 37. Hart D, Ward M, Lifschitz M: Suprofen-related nephrotoxicity: A distinct clinical syndrome. Ann Intern Med 1987;106:235-238.Crossref

Journal

Archives of Internal MedicineAmerican Medical Association

Published: Jul 1, 1987

There are no references for this article.